Novartis (VTX:NOVN) received a CHF 105 price objective from equities researchers at Goldman Sachs Group in a research report issued to clients and investors on Friday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock.
Several other research analysts have also issued reports on the stock. HSBC set a CHF 88 price target on shares of Novartis and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Barclays set a CHF 80 price target on shares of Novartis and gave the stock a “sell” rating in a research report on Thursday, September 5th. Bank of America set a CHF 104 price target on shares of Novartis and gave the stock a “buy” rating in a research report on Friday. Kepler Capital Markets set a CHF 87 price target on shares of Novartis and gave the stock a “buy” rating in a research report on Tuesday, May 21st. Finally, Deutsche Bank set a CHF 90 price objective on shares of Novartis and gave the stock a “neutral” rating in a research report on Monday. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. Novartis has an average rating of “Hold” and an average price target of CHF 90.85.
Novartis has a 12-month low of CHF 72.45 and a 12-month high of CHF 88.30.
Novartis Company Profile
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Recommended Story: Stock Symbol
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.